This database contains 123 studies, archived under the term: "cholinesterase inhibitors"
Click here to filter this large number of results.
Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease
Penner, Jacob,
Rupsingh, Raul,
Smith, Matthew,
Wells, Jennie L.,
Borrie, Michael J.,
Bartha, Robert
Galantamine is a cholinesterase inhibitor and allosteric potentiating ligand modulating presynaptic nicotinic acetylcholine receptors that is used in the treatment of Alzheimer disease (AD). The purpose of this study was to determine if galantamine treatment would result in detectable hippocampal metabolite changes that correlated with changes in cognition, as measured by the Mini-Mental State Examination […]
Short-term effect of combined drug therapy and cognitive stimulation therapy on the cognitive function of Alzheimer’s disease
Matsuda, Osamu,
Shido, Emi,
Hashikai, Ayako,
Shibuya, Haruka,
Kouno, Mitsue,
Hara, Chizuko,
Saito, Masahiko
Background: Acetylcholinesterase inhibitors (i.e. donepezil) are known to benefit Alzheimer’s disease (AD) patients. However, the combined effects of acetylcholinesterase and cognitive stimulation therapy (CST) are still debated. The present study examined their combined effects on the progression of cognitive decline in AD.; Methods: The present study was a non-randomized controlled study and included two groups […]
Effects of rivastigmine on common symptomatology of Alzheimer’s disease (EXPLORE)
Objective: To evaluate, in a real-world clinical setting, the efficacy of rivastigmine in the management of six symptoms commonly associated with Alzheimer’s disease (AD).; Methods: This was a naturalistic, prospective, open-label, multi-centre, post-marketing, observational study. Data were collected by the participating study physicians at their practices across Canada. Subjects had a clinical diagnosis of mild-to-moderate […]
Comparative cardiovascular safety of dementia medications: a cross-national study
Fosbøl, Emil L.,
Peterson, Eric D.,
Holm, Ellen,
Gislason, Gunnar H.,
Zhang, Yinghong,
Curtis, Lesley H.,
Køber, Lars,
Iwata, Isao,
Torp-Pedersen, Christian,
Setoguchi, Soko
Objectives: To compare the cardiovascular safety of currently marketed dementia medications in new users in the United States and Denmark.; Design: Retrospective cohort study.; Setting: Nationally representative sample of Medicare beneficiaries from 2006 through 2009 and nationwide Danish administrative registries from 1997 through 2007.; Participants: Individuals treated with a dementia medication aged 65 and older.; […]
Rivastigmine patch for treatment of Alzheimer’s disease in clinical practice in Thailand
Kulkantrakorn, Kongkiat,
Tanyakitpisal, Panas,
Towanabut, Somchai,
Dejthevaporn, Charungthai,
Rangseekajee, Poonsri,
Pongpakdee, Sunsanee,
Laptikultham, Somsak,
Rodprasert, Kritsada,
Setthawatcharawanich, Suwanna,
Thinkhamrop, Bandit
Background: Rivastigmine is a cholinesterase inhibitor for treatment of mild to moderate Alzheimer’s disease (AD) and dementia associated with Parkinson’s disease. The new patch formulation was recently made available. We assessed the safety, tolerability, and cognitive outcome of rivastigmine patch in treatment of mild to moderate AD in clinical practice in Thailand.; Methods: A multicentre, […]
A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer’s disease
Akhondzadeh, Shahin,
Shafiee Sabet, Mehdi,
Harirchian, Mohammad Hossein,
Togha, Mansoreh,
Cheraghmakani, Hamed,
Razeghi, Soodeh,
Hejazi, Seyyed Shamssedin,
Yousefi, Mohammad Hossein,
Alimardani, Roozbeh,
Jamshidi, Amirhossein,
Rezazadeh, Shams-Ali,
Yousefi, Aboulghasem,
Zare, Farhad,
Moradi, Atbin,
Vossoughi, Ardalan
Rationale: There is increasing evidence to suggest the possible efficacy of Crocus sativus (saffron) in the management of Alzheimer’s disease (AD).; Objective: The purpose of the present investigation was to assess the efficacy of C. sativus in the treatment of patients with mild-to-moderate AD.; Methods: Fifty-four Persian-speaking adults 55 years of age or older who […]
Safety and tolerability of galantamine in possible Alzheimer’s disease with or without cerebrovascular disease and vascular dementia in Thai patients
Senanarong, Vorapun,
Poungvarin, Niphon,
Phanthumchinda, Kammant,
Thavichachart, Nuntika,
Chankrachang, Siwaporn,
Praditsuwan, Rungnirund,
Nidhinandana, Samart
The purpose of this study was to explore factors that influence the clinical safety and tolerability associated with galantamine administration in Thai Alzheimer’s disease patients with or without cerebrovascular disease and vascular dementia. This was an analysis of previous study. Tolerability and safety profile were analyzed according to sex, age, body weight, Thai mental state […]
Galantamine (reminyl) in the treatment of severe Alzheimer’s disease
Twenty-five patients with Alzheimer’s disease (AD) in moderate-severe and severe stages received galantamine in dosage 8 mg daily during the 1st month with the following increasing to 16 mg daily. Six patients received 24 mg per day from the 3rd month. The total duration of therapy was 26 weeks. 15 patients received in addition the […]
A phase I trial of deep brain stimulation of memory circuits in Alzheimer’s disease
Laxton, Adrian W.,
Tang-Wai, David F.,
McAndrews, Mary Pat,
Zumsteg, Dominik,
Wennberg, Richard,
Keren, Ron,
Wherrett, John,
Naglie, Gary,
Hamani, Clement,
Smith, Gwenn S.,
Lozano, Andres M.
Objective: Alzheimer disease (AD) is characterized by functional impairment in the neural elements and circuits underlying cognitive and memory functions. We hypothesized that fornix/hypothalamus deep brain stimulation (DBS) could modulate neurophysiological activity in these pathological circuits and possibly produce clinical benefits.; Methods: We conducted a phase I trial in 6 patients with mild AD receiving […]